Product
Indication
In Vitro Confirmationof Lead Candidate
Efficacy Study in Animal Model
Candidate Confirmation
Pre-clinical
Clinical
Bispecific Antibody
BAB-05
Hematological malignancies
Pre-clinical---IND expected in 2025-Q4
BAB-09
Prostate Cancer
Pre-clinical
BAB-0120
NSCLC
Pre-clinical
AF-29
Autoimmune and Inflammatory diseases
Pre-clinical--- IND expected in 2025-Q4
BIC-020
Colorectal Cancer
Pre-clinical
BIC-021
HSNCC/solid tumor
Candidate Confirmation
lCM-053
Solid/Hematological cancer
Pre-clinical
ICM-022
Castration -resistant prostate cancer
Pre-clinical
ICM-051
Solid cancer
Candidate Confirmation
Bispecific Antibody Conjugates
BTA-010
NSCLC
Pre-clinical---IND expected in 2026-Q1
BTA-032
Prostate Cancer
Candidate Confirmation
BTA-0120
AML
Efficacy Study in Animal Model
Recombinant Proteins
Monoclonal Antibodies
Epitope-directed mAbs
MAB105
Immune modulator/Sepsis/RA
Pre-clinical